[Mycophenolate mofetil in the treatment of selected connective tissue diseases].
Mycophenolate mofetil (MMF) is an inhibitor of inosine monophosphate dehydrogenase, which affects de novo purine synthesis and T- and B-cell proliferation. So far its efficacy and safety as an immunosuppressive treatment have been proven in organ transplantations and also in various autoimmune diseases. A literature search was conducted by using PubMed and the Cochrane library. This review focuses primarily on current treatment with MMF for systemic lupus erythematosus, systemic sclerosis, vasculitis and idiopathic inflammatory myopathies.
Małopolskie Centrum Reumatologii, Immunologii i Rehabilitacji, Oddział Reumatologii Szpitala Specjalistycznego im. J. Dietla w Krakowie. bogbat@poczta.onet.pl
Bogdan
B
Batko
Małopolskie Centrum Reumatologii, Immunologii i Rehabilitacji, Oddział Reumatologii Szpitala Specjalistycznego im. J. Dietla w Krakowie.
Piotr
P
Krawiec
Małopolskie Centrum Reumatologii, Immunologii i Rehabilitacji, Oddział Reumatologii Szpitala Specjalistycznego im. J. Dietla w Krakowie.
Jolanta
J
Osieleniec
Katedra i Klinika Nefrologii Uniwersytet Jagielloński, Collegium Medicum w Krakowie.
Władysław
W
Sułowicz
D003240:Connective Tissue Diseases / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009220:Myositis / Q000188:drug therapy; D012595:Scleroderma, Systemic / Q000188:drug therapy; D014657:Vasculitis / Q000188:drug therapy
D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid